T&L Biotechnology

Product Name

Generic Name

Recombinant Human FLT3 Ligand Protein

Synonym

FLT3LG,FL,FLT3L,Flt3 ligand

Product Information

Construction

A DNA sequence encoding the human FLT3 Ligand（NP_001450.2）was expressed with a His                                                            tag at the C-terminus.

Expression Host

HEK293 cells

QC Testing Purity

> 90 % as determined by SDS-PAGE

Activity

Determined by the dose-dependent stimulation of the proliferation of AML5 cells.The expected ED ₅₀ for this effect is ≤ 10 ng/ml.

Endotoxin

< 0.1EU per 1μg of the protein as determined by the LAL method.

Molecular Mass

The recombinant human FLT3 Ligand protein contains 161 amino acids with a predicted molecular weight of 18.4 kD.

Formulation

Lyophilized from sterile PBS, pH 7.4. Normally 6 % mannitol are added as protectants before lyophilization.

Stability & Storage

24 months at 2℃ to 8℃ in lyophilized state. 

6 months at -20℃ under sterile conditions after reconstitution.

12 months at -80℃ under sterile conditions after reconstitution.

Recommend to aliquot the protein into smaller quantities after reconstituting with water for injection, normal saline or PBS, and keep the diluted concentration above 100μg/mL.

Avoid repeated freeze-thaw cycles.

Background

FLT3 ligand is a growth factor that regulates the proliferation of early hematopoietic cells. FLT 3-ligand binds to cells expressing tyrosine kinase receptor FLT3. The FLT3 ligand itself does not stimulate the proliferation of early hematopoietic cells, but rather synergistically induces growth and differentiation with other CSFs and interleukins. Unlike SCF, FLT3 ligand has no effect on mast cell. Multiple subtypes of FLT3-ligands have been identified.The main bioactive form is anchored on the cell surface as the extracellular domain of transmembrane protein (209 a.). The membrane binding isomers can be cleaved by proteins to form biologically active soluble isomers.

References 

1. Measurable residual disease (MRD) monitoring by NGS before allogeneic hematopoietic cell transplantation in AML.Thol F, Gabdoulline R, Liebich A, Klement P, Schiller J, Kandziora C, Hambach L, Stadler M, Koenecke C, Flintrop M, Pankratz M, Wichmann M, Neziri B, Büttner K, Heida B, Klesse S, Chaturvedi A, Kloos A, Göhring G, Schlegelberger B, Gaidzik VI, Bullinger L, Fiedler W, Heim A, Hamwi I, Eder M, Krauter J, Schlenk RF, Paschka P, Döhner K, Döhner H, Ganser A, Heuser M.Blood. 2018 Sep 6. pii: blood-2018-02-829911. doi: 10.1182/blood-2018-02-829911.

2. Absence of FLT3 mutations in Iranian adult T-cell leukemia/lymphoma patients.Ayatollahi H, Sadeghian M, Kooshyar M, Shirdel A, Rahimi H, Jafarian A, Ghazaei S, Soltani N, Shams F, Motamedi Rad N, Shakeri S.Med J Islam Repub Iran. 2018 Jun 9;32:47. doi: 10.14196/mjiri.32.47. eCollection 2018.

Trial dosage: A customer can apply for up to five samples a year (the actual trial dosage is determined by telephone or email communication).
Scope of use: Samples are limited to testing and research purposes.
Cost: Free for samples, customer is responsible for shipping and handling charges, reference cost is $50 in the US, €60 in the EU, and $50 in other countries.
How to apply: You can apply by telephone or by email (the email application should specify the sample name, item number, contact person, telephone number, consignee address, etc.).